Detailed Narrative
FY25 Financial Performance Highlights
Krsnaa Diagnostics reported a strong FY25, with revenue growing 16% year-on-year to ₹7,172 million. EBITDA increased by 34% to ₹1,958 million, and margins expanded by 370 basis points to 27%, showcasing robust operating leverage. Net profit also saw significant growth of 37% to ₹776 million, achieving an 11% margin. For Q4 FY25, revenue stood at ₹1,861 million, a 12% YoY increase, with EBITDA at ₹542 million, up 23% YoY, and a 29% margin.
Strategic Model and Market Position
The company emphasized its unique PPP-based model, which enables it to offer high-quality diagnostics at prices 60-70% lower than market rates while maintaining sustainable EBITDA margins of 25-27%. In FY25, Krsnaa served over 19 million patients and conducted over 61 million tests, demonstrating its model's resilience. The company believes it is not just following the market but actively helping to build it, especially in underserved geographies.
Retail Expansion and Future Outlook
Krsnaa's retail footprint, operating under the RPL brand, expanded significantly, growing 4x in one year across Maharashtra, Punjab, Assam, and Orissa. Retail contributed approximately 3.5% to the overall revenue in Q4 FY25, with a target to increase this to 5-8% in FY26. The long-term aspiration for the retail B2C/B2B mix is 70:30, with B2C offering better margins and being a key growth driver.
Receivables Management and Challenges
As of March 31, 2025, receivables stood at 128 days, primarily due to transitional delays in Himachal Pradesh and Karnataka, where ₹140-150 crores were outstanding. Management acknowledged these delays were due to NHM funds allocation and procedural aspects but expressed confidence in normalizing receivable days to around 100-odd days by FY26, citing ongoing system implementations and strong stakeholder relationships.
Impact of Project Delays and Tender Decisions
FY25 revenue growth of 16% was below the aspirational 20-25% due to external timing factors, including delays in site handovers for Maharashtra CT MRI projects and the early conclusion of the BMC project due to budget exhaustion. The company also strategically decided not to pursue the new BMC tender, as revised conditions and budgetary caps would have made it unprofitable, prioritizing long-term profitability over short-term volume.
Capital Expenditure and Growth Plans
The company's FY25 capex was ₹111 crores, primarily allocated to new radiology centers in Madhya Pradesh, Maharashtra, and Delhi, as well as pathology collection centers in Assam and Orissa. For FY26, the planned capex is between ₹100-150 crores, with the practical cash outflow expected to be less than ₹100 crores, reflecting an asset-light expansion strategy. This capex supports the expansion of PPP leadership and retail footprint.
Radiology and Pathology Mix Evolution
The revenue mix for FY25 was 50:50 between radiology and pathology, a shift from FY24's 60:40 split (radiology:pathology). Management anticipates a higher share of growth from the radiology business in the coming quarters due to a strong pipeline of radiology tenders. The company continues to focus on integrated diagnostic offerings, including teleradiology, and maintaining high-quality accreditations.